Once-daily Trelegy Ellipta gains expanded indication in U.S. for patients with COPD
GlaxoSmithKline and Innoviva announced the FDA has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means Trelegy Ellipta can now be used by US physicians to treat a broader population of COPD. April 24, 2018